Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Eldelumab in active ulcerative colitis
NCT01294410Phase 2Completed
- Sponsor
- Bristol Myers Squibb
- Start
- Mar 2011
- Primary completion
- Dec 2012
- Modality
- Monoclonal Antibodies
- Countries
- 14
01
Overview
Phase 2, randomised, double-blind trial of eldelumab in ulcerative colitis (UC) (5 arms), sponsored by Bristol Myers Squibb. Primary endpoint: Proportion of subjects with clinical remission at 11 weeks. Started Mar 2011; status: completed.
02
Drugs
eldelumab
03
Conditions
ulcerative colitis (UC)
Beyond the preview
Go deeper on NCT01294410.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT01294410.